千金药业(600479) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥866,103,121.71, a decrease of 12.00% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2023 was ¥80,197,113.64, an increase of 10.72% year-on-year[5] - Basic earnings per share for Q3 2023 were ¥0.1868, up by 10.86% compared to the previous year[6] - Total operating revenue for the first three quarters of 2023 was CNY 2,778,909,669.96, a decrease of 4% compared to CNY 2,894,932,737.23 in the same period of 2022[20] - Net profit for the third quarter of 2023 was CNY 239,614,142.84, an increase of 6.9% from CNY 224,115,492.32 in the same quarter of 2022[21] - Earnings per share for the third quarter of 2023 was CNY 0.4586, compared to CNY 0.4355 in the same quarter of 2022, reflecting a growth of 5.7%[22] - The company reported a total comprehensive income of CNY 239,803,274.97 for the third quarter of 2023, compared to CNY 224,916,132.23 in the same quarter of 2022, indicating an increase of 6.6%[22] Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥4,490,339,384.59, a decrease of 2.85% from the end of the previous year[6] - The total current assets as of September 30, 2023, amount to RMB 3,397,798,882.69, a decrease from RMB 3,513,491,527.41 at the end of 2022[15] - The total assets as of September 30, 2023, are RMB 4,490,339,384.59, down from RMB 4,621,975,680.77 at the end of 2022[16] - Total current liabilities as of September 30, 2023, are RMB 1,512,887,445.21, compared to RMB 1,697,221,863.57 at the end of 2022[16] - Total liabilities as of the end of the third quarter of 2023 were CNY 1,606,604,039.87, a decrease of 11% from CNY 1,805,690,959.18 at the end of the previous year[21] Cash Flow - Cash flow from operating activities showed a significant decline of 82.63% year-to-date, totaling ¥74,034,264.45[6] - In the first three quarters of 2023, the net cash flow from operating activities was ¥74,034,264.45, a significant decrease of 82.6% compared to ¥426,271,591.71 in the same period of 2022[24] - Total cash inflow from operating activities decreased to ¥2,915,711,268.33, down 12% from ¥3,310,502,702.85 in the previous year[24] - Cash outflow from operating activities increased to ¥2,841,677,003.88, compared to ¥2,884,231,111.14 in the previous year, indicating a slight increase of 1.5%[24] - Cash flow from investment activities showed a net inflow of ¥591,571,484.02, a substantial increase from ¥63,643,241.43 in the same period last year[25] - Cash inflow from investment activities totaled ¥981,273,801.23, down 42.5% from ¥1,708,828,332.15 in the previous year[25] - Cash outflow from investment activities decreased significantly to ¥389,702,317.21 from ¥1,645,185,090.72, a reduction of 76.3%[25] - Cash flow from financing activities resulted in a net outflow of ¥193,880,822.44, an improvement from a net outflow of ¥249,754,425.00 in the previous year[25] - The ending cash and cash equivalents balance increased to ¥1,573,660,040.48, compared to ¥750,661,180.56 at the end of the previous year, reflecting a growth of 109.5%[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 39,646[12] - The largest shareholder, Zhuzhou State-owned Assets Investment Holding Group Co., Ltd., holds 119,381,136 shares, accounting for 27.8% of total shares[12] - The company’s equity attributable to shareholders increased by 2.78% to ¥2,277,922,463.38 compared to the end of the previous year[6] - Total equity attributable to shareholders of the parent company increased to CNY 2,277,922,463.38, up from CNY 2,216,214,931.35, representing a growth of 2.8%[21] Research and Development - Research and development expenses increased by 35.31%, reflecting the company's commitment to enhancing its R&D efforts[10] - Research and development expenses for the first three quarters of 2023 amounted to CNY 111,291,724.78, an increase of 35.4% from CNY 82,246,441.82 in the previous year[21] - The company has ongoing research and development expenditures amounting to RMB 24,196,986.92[16]